Moleculin Biotech Inc reports results for the quarter ended in December - Earnings Summary

Moleculin Biotech

22/03/2024 22:21

* Moleculin Biotech Inc  MBRX.OQ  reported a quarterly
adjusted
loss of $5.02​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of $-3.45.  The mean expectation of three analysts for the
quarter was for a loss of $3.05 per share. Wall Street expected
results to range from $-3.15 to $-2.85 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Moleculin Biotech Inc's reported EPS for the quarter was a
loss
of $5.02​.
    * The company reported a quarterly loss of $10.27 million.
    * Moleculin Biotech Inc shares had fallen by 48.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Moleculin Biotech
Inc is $45.00 
This summary was machine generated from LSEG data March 22 at
10:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -3.05          -5.02          Missed
 Sep. 30 2023      -3.55          -2.85          Beat
 Jun. 30 2023      -4.10          -3.00          Beat
 Mar. 31 2023      -3.75          -4.20          Missed